Corcept Therapeutics Incorporated

CORT

$2.69B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaREDWOOD CITY500 employees

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 18, 2026

10d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

10 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date CORT125134 (standard)

2/18/2026

For Cushing's syndrome. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date CORT118335 (standard)

4/9/2026

For Antipsychotic for Psychosis Associated with Alzheimer's Dementia. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date Relacorilant (standard)

5/1/2026

For Cushing's syndrome. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date Relacorilant (standard)

5/12/2026

For Cushing's syndrome. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date NDA for relacorilant (standard)

6/25/2026

For Cushing's syndrome. NDA filing. Extracted from SEC filing: 8-K

Source

Phase 2

Relacorilant 150 mg once daily (QD) Phase 2 Results Expected

August 2026~Relacorilant 150 mg once daily (QD)270

Primary completion for Relacorilant 150 mg once daily (QD) trial (NCT06906341) in Ovarian Cancer

Source

Phase 2

Nab-paclitaxel 80 mg/m^2 Phase 2 Results Expected

August 2026~Nab-paclitaxel 100 mg/m^2270

Primary completion for Nab-paclitaxel 80 mg/m^2 trial (NCT06906341) in Ovarian Cancer

Source

Phase 2

Dazucorilant 300 mg Phase 2 Results Expected

September 2026~Dazucorilant 300 mg279

Primary completion for Dazucorilant 300 mg trial (NCT05407324) in Amyotrophic Lateral Sclerosis

Source

Phase 2

Nenocorilant 200 mg Phase 2 Results Expected

September 2026~Nenocorilant 200 mg50

Primary completion for Nenocorilant 200 mg trial (NCT07276373) in Neoplasms

Source

Phase 2

Miricorilant (Cohort A) Phase 2 Results Expected

September 2026~Miricorilant (Cohort A)175

Primary completion for Miricorilant (Cohort A) trial (NCT06108219) in Nonalcoholic Steatohepatitis (NASH)

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Mifepristone

Phase 3

Depressive Disorder, Major

Relacorilant 150 mg once daily (QD)

Phase 3

Ovarian Cancer

Nab-paclitaxel 100 mg/m^2

Phase 3

Ovarian Neoplasm

Relacorilant

Phase 3

Recurrent Ovarian Cancer

mifepristone 600 mg

Phase 3

Major Depressive Disorder

Miricorlilant

Phase 2

Antipsychotic-induced Weight Gain (AIWG)

Dazucorilant 300 mg

Phase 2

Amyotrophic Lateral Sclerosis

Relacorilant with nab-paclitaxel

Phase 2

Solid Tumors

Nenocorilant 200 mg

Phase 2

Neoplasms

Gemcitabine 1000 mg/m^2

Phase 2

Adenocarcinoma

CORT125281

Phase 2

Metastatic Castration-Resistant Prostate Cancer

Miricorilant

Phase 2

Antipsychotic-induced Weight Gain (AIWG)

CORT125134

Phase 2

Cushing's Syndrome

Miricorilant (Cohort A)

Phase 2

Nonalcoholic Steatohepatitis (NASH)

Drug Name	Phase	Indication	Designations
Mifepristone	Phase 3	Depressive Disorder, Major	-
Relacorilant 150 mg once daily (QD)	Phase 3	Ovarian Cancer	-
Nab-paclitaxel 100 mg/m^2	Phase 3	Ovarian Neoplasm	-
Relacorilant	Phase 3	Recurrent Ovarian Cancer	-
mifepristone 600 mg	Phase 3	Major Depressive Disorder	-
Miricorlilant	Phase 2	Antipsychotic-induced Weight Gain (AIWG)	-
Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis	-
Relacorilant with nab-paclitaxel	Phase 2	Solid Tumors	-
Nenocorilant 200 mg	Phase 2	Neoplasms	-
Gemcitabine 1000 mg/m^2	Phase 2	Adenocarcinoma	-
CORT125281	Phase 2	Metastatic Castration-Resistant Prostate Cancer	-
Miricorilant	Phase 2	Antipsychotic-induced Weight Gain (AIWG)	-
CORT125134	Phase 2	Cushing's Syndrome	-
Miricorilant (Cohort A)	Phase 2	Nonalcoholic Steatohepatitis (NASH)	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

CORT News